Market Closed -
Nasdaq
04:00:00 2024-04-29 pm EDT
5-day change
1st Jan Change
21.53
USD
+5.85%
+9.79%
-0.23%
Presentation Operator MessageOperator (Operator)Good afternoon, and welcome to Castle Bioscien...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Castle Biosciences Insider Sold Shares Worth $441,853, According to a Recent SEC Filing
Apr. 08
MT
Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress
Apr. 04
CI
Castle Biosciences, Inc. Announces Board Changes
Mar. 27
CI
Castle Biosciences, Inc. Announces the Publication of an Expert Consensus Article in the Journal of Clinical and Aesthetic Dermatology
Mar. 19
CI
Castle Biosciences, Inc. Announces the Publication of a New Multi-Center Performance Study of its DecisionDx-SCC Risk Stratification Test
Mar. 07
CI
Transcript : Castle Biosciences, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Feb. 28
Earnings Flash (CSTL) CASTLE BIOSCIENCES Posts Q4 Revenue $66.1M, vs. Street Est of $61.2M
Feb. 28
MT
Castle Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 28
CI
Castle Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024
Feb. 28
CI
Castle Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Feb. 28
CI
Castle Biosciences Insider Sold Shares Worth $493,818, According to a Recent SEC Filing
Feb. 07
MT
Castle Biosciences, Inc. Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii
Jan. 14
CI
Castle Biosciences Insider Sold Shares Worth $475,585, According to a Recent SEC Filing
Jan. 08
MT
Castle Biosciences Sees 53% Growth in Annual Revenue in 2023
Jan. 08
MT
Castle Biosciences, Inc. Provides Revenue Guidance for the Year 2023
Jan. 07
CI
Castle Biosciences Insider Sold Shares Worth $301,774, According to a Recent SEC Filing
Dec. 29
MT
Castle Biosciences Insider Sold Shares Worth $260,466, According to a Recent SEC Filing
Dec. 27
MT
Castle Biosciences Insider Sold Shares Worth $393,446, According to a Recent SEC Filing
Dec. 22
MT
Castle Biosciences Insider Sold Shares Worth $334,542, According to a Recent SEC Filing
Dec. 21
MT
Castle Biosciences Insider Sold Shares Worth $496,967, According to a Recent SEC Filing
Dec. 18
MT
Guggenheim Initiates Castle Biosciences With Buy Rating, $25 Price Target
Dec. 14
MT
Castle Biosciences Insider Sold Shares Worth $278,590, According to a Recent SEC Filing
Dec. 05
MT
Castle Biosciences Insider Sold Shares Worth $593,574, According to a Recent SEC Filing
Dec. 01
MT
Castle Biosciences Insider Sold Shares Worth $430,800, According to a Recent SEC Filing
Dec. 01
MT
Castle Biosciences Insider Sold Shares Worth $112,377, According to a Recent SEC Filing
Nov. 22
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.
More about the company
Last Close Price
21.53
USD
Average target price
33.11
USD
Spread / Average Target
+53.79%
Consensus
1st Jan change
Capi.
-0.23% 561M +1.69% 12.8B -7.57% 7.61B +3.22% 5.41B +0.93% 4.51B +8.48% 4.49B +9.21% 2.73B -13.87% 2.02B -11.63% 1.73B +3.45% 1.64B
Diagnostic & Testing Substances
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1